Shoulder Impingement Syndrome
Conditions
Interventions
Control group (Study 1):Oral administration of celecoxib capsules (once daily for 2 weeks) for 2 weeks.
Trial Group 1 (Study 1):Oral administration of celecoxib capsules (once a day for 2 weeks) combined with shock wave therapy (days 7 and 14, twice in total) for 2 weeks
Trial Group 2 (Study 1):Oral administration of celecoxib capsules (once a day for 2 weeks) combined with shock wave therapy (7 days and 14 days, twice in total) and shoulder exercises (3 groups daily
Trial Group (Study II):Under ultrasound guidance, needle-knife release of the coracoacromial ligament was performed, with a single treatment session followed by scheduled in-person follow-ups.
Sponsors
Wangjing Hospital, China Academy of Chinese Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: Study 1 1. Meet diagnostic criteria and voluntarily participate in the trial with informed consent signed; 2. Adult patients aged over 18 and under 75 years, regardless of gender; 3. In Neer stage I–II; 4. X-ray shows acromion morphology as Bigliani type I or II; 5. Good compliance and willingness to cooperate with related treatment. Study 2 1. Meet diagnostic criteria and voluntarily participate in the trial with informed consent signed; 2. Adult patients aged over 18 and under 75 years, regardless of gender; 3. In Neer stage I–II; 4. X-ray shows acromion morphology as Bigliani type I or II; 5. Good compliance and willingness to cooperate with related treatment.
Exclusion criteria
Exclusion criteria: Study 1 1. Patients with chronic underlying diseases, skin breakdown or infection tendency, pregnancy, shoulder tumors, congenital shoulder maldevelopment, or intolerance to shock wave therapy; those unable to complete MRI or with prior allergy to celecoxib; 2. Patients receiving other concurrent treatments such as oral analgesics or acupuncture that may affect trial efficacy; 3. Patients with psychiatric abnormalities who are unable to cooperate with treatment or data collection and have poor compliance; 4. Patients concurrently suffering from stiff-phase frozen shoulder. Study 2 1. Patients with chronic underlying diseases, skin breakdown or infection tendency, pregnancy, shoulder tumors, congenital shoulder maldevelopment, or intolerance to shock wave therapy; those unable to complete MRI; 2. Patients receiving other concurrent treatments such as oral analgesics or acupuncture that may affect trial efficacy; 3. Patients with psychiatric abnormalities who are unable to cooperate with treatment or data collection and have poor compliance; 4. Patients concurrently suffering from stiff-phase frozen shoulder.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| SPADI score;Constant-Murley score of shoulder joint; | — |
Secondary
| Measure | Time frame |
|---|---|
| Proprioceptive assessment;VAS score;UCLA score;Patient global impression change score; | — |
Countries
China
Contacts
Public ContactJin Zhefeng
Wangjing Hospital, China Academy of Chinese Medical Sciences
Outcome results
None listed